

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Nuformix plc
("Nuformix" or the "Company")

**Result of General Meeting
and
Total Voting Rights**

London, UK – 29 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, further to the announcement made in connection with the Placing on 10 March 2021, at the General Meeting held earlier today all Resolutions put to Shareholders were duly passed.

Accordingly, the Company has raised, in aggregate, gross proceeds of £1.565 million.

Applications have been made to the FCA for the Placing Shares to be admitted to the Official List and to the London Stock Exchange for the Placing Shares to be admitted to trading on the Main Market of the London Stock Exchange. It is expected that Admission will become effective at 8:00 a.m. on 30 March 2021 and that dealings in the Placing Shares will commence at that time.

Total Voting Rights

On Admission, the Company will have 591,609,368 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares and voting rights will be 591,609,368 and this figure may be used by Shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular dated 10 March 2021, a copy of which is available to view on the Company's website (www.nuformix.com).

Enquiries:

Nuformix plc +44 (0)1223 627222
Dr Anne Brindley, CEO
Fleur Wood, Investor Relations

Allenby Capital Limited +44 (0)203 328 5656
Tim Sohal / Matt Butlin (Sales and Corporate Broking)
Nick Athanas / George Payne (Corporate Finance)

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new

indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.